中科微点-全球专利检索

  1. Login
  2. Sign Up

Search Results

286 records (took 0.039 seconds)

    THERAPEUTIC USE OF SPECIFIC LIGAND IN MSRV ASSOCIATED DISEASES
    195.
    发明公开
    THERAPEUTIC USE OF SPECIFIC LIGAND IN MSRV ASSOCIATED DISEASES 有权
    治疗师EINSATZ SPEZIFISCHER LIGANDEN BEI MIT MSRV ASSOZIIERTEN KRANKHEITEN

    公开(公告)号：EP2315777A1

    公开(公告)日：2011-05-04

    申请号：EP09780311.8

    申请日：2009-07-08

    Applicant: Geneuro SA

    Inventor： BERNARD, Corinne ,  LANG, Alois, Bernhardt ,  PERRON, Hervé ,  BERTRAND, Jean-Baptiste

    IPC: C07K16/10 ,  A61K39/42

    CPC classification number: C07K16/1036 ,  A61K2039/505 ,  C07K2317/24 ,  C07K2317/56 ,  C07K2317/565 ,  C07K2317/92

    Abstract: The present invention deals with a ligand comprising each of the complementary-determining regions (CDRs) set forth in SEQ ID No. 1, SEQ ID No. 2, SEQ ID No. 3 SEQ ID No. 4, SEQ ID No. 5 and SEQ ID No. 6 for use in a method of treatment.

    Abstract translation: 本发明涉及包含SEQ ID No.1，SEQ ID No.2，SEQ ID No.3，SEQ ID No.4，SEQ ID No.5所示的每个互补决定区（CDR）和 SEQ ID No.6或在所述序列中具有任何数目的取代的氨基酸的序列，如下所示，CDR1（SEQ ID No.1）中为0至3，CDR2（SEQ ID No.2）为0至2， CDR4（SEQ ID No.3）中为0至2，CDR4（SEQ ID No.4）为0至1，CDR5（SEQ ID No.5）为0至4，CDR6（SEQ ID NO：0）为0至2 ID 6），或在所述序列SEQ ID No.1至SEQ ID No.6内具有等同化学功能和性质的其它氨基酸取代的氨基酸。

    DOMAINE PEPTIDIQUE NECESSAIRE A L'INTERACTION ENTRE L'ENVELOPPE D'UN VIRUS APPARTENANT AU GROUPE D'INTERFERENCE DE HERV-W ET UN RECEPTEUR HASCT
    198.
    发明公开
    DOMAINE PEPTIDIQUE NECESSAIRE A L'INTERACTION ENTRE L'ENVELOPPE D'UN VIRUS APPARTENANT AU GROUPE D'INTERFERENCE DE HERV-W ET UN RECEPTEUR HASCT 有权
    肽结构域从HERV-W病毒的情况下，足以与甲HASCT受体相互作用

    公开(公告)号：EP1981904A2

    公开(公告)日：2008-10-22

    申请号：EP07730950.8

    申请日：2007-02-09

    Applicant: Biomerieux S.A.

    Inventor： MALLET, François ,  ORIOL, Guy ,  CHEYNET, Valérie

    IPC: C07K14/15

    CPC classification number: C07K14/005 ,  A61K38/162 ,  A61K39/12 ,  A61K39/21 ,  C07K16/1036 ,  C07K2317/34 ,  C12N7/00 ,  C12N2740/10022 ,  C12N2740/10034 ,  C12N2740/10063 ,  G01N2333/15

    Abstract: The invention relates to a peptide domain required for interaction between the envelope of a virus pertaining to the HERV-W interference group and an hASCT receptor, comprising an N end point and a C end point. Said peptide domain is defined, at the N end point thereof, by a pattern formed by the amino acids L (Z)α-proline-cysteine-X-cysteine in which Z is any amino acid, α is a whole number between 2 and 30, and X is any amino acid, and at the C end point thereof, by a pattern formed by the amino acids serine-aspartic acid-Xa-Xb-Xc-Xd-Xe-aspartic acid-Xf Xg-(Z)β in which Xa, Xb, Xc, Xd, Xe, Xf Xg are any amino acids, Z is any amino acid, β is a whole number between 15 and 25, preferably 20. The peptide domain comprises, between the N end point and the C end point , at least one pattern selected from the following patterns: a pattern formed by the amino acids cysteine-tyrosine-X2-X3-X4-X5- X6-cysteine in which X2, X3, X4, X5, X6 are any amino acids, and a pattern formed by the amino acids cysteine-X7-X8-X9-X10-X11- X12- X13-X14-X15-cysteine-trytophane in which X7, X8, X9, X10, X11, X12, X13, X14, X15 are any amino acids.

    METHOD FOR DETECTING REPLICATION COMPETENT VIRUSES IN THE SERA OF SUBJECTS RECEIVING GENE THERAPY
    199.
    发明公开
    METHOD FOR DETECTING REPLICATION COMPETENT VIRUSES IN THE SERA OF SUBJECTS RECEIVING GENE THERAPY 审中-公开
    FOR REPLICATION CAPABLE病毒的血清纳税人的检测方法得到GENTHERARIE。

    公开(公告)号：EP1240361A4

    公开(公告)日：2005-01-12

    申请号：EP00976429

    申请日：2000-11-15

    Applicant: VIROMED LTD

    Inventor： KIM SUN-YOUNG ,  PARK EUN-JIN ,  NA YOUNG-SOON ,  YU SEUNG-SHIN

    IPC: G01N33/53 ,  C07K16/10 ,  C12N15/09 ,  C12Q1/70 ,  G01N33/569

    CPC classification number: C07K16/1036

    Abstract: The present invention provides a method for detecting replication competent viruses in the sera of subjects receiving gene therapy, the method comprising the step of detecting anti-retroviral antibodies in the sera using a specific antigen. A gene for the antigen exists not in a viral vector for gene therapy but only in a virus genome from which the viral vector originated and the antigen is preferably selected from the group of partial Gag and partial Env proteins of murine leukemia virus. There are also provided antigens whose amino acid sequences include the sequence of SEQ ID NO: 2 or SEQ ID NO: 6, which is of great use in immunoreaction-based RCR detection in view of specificity and sensitivity.

Patent Agency Ranking